Welcome to our dedicated page for Dariohealth news (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on Dariohealth stock.
DarioHealth Corp. develops digital health and digital therapeutics solutions for people managing chronic conditions. The company’s multi-condition platform uses data analytics, connected health devices, personalized interventions and one-on-one coaching across diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
DRIO news commonly covers quarterly financial results, conference calls, commercial activity with health plans, payers, self-insured employers, care providers and consumers, and clinical research based on real-world platform data. Other recurring updates include AI-enabled product development such as DarioIQ, evidence publications, board and governance changes, and capital or credit arrangements supporting the company’s digital health business.
DarioHealth Corp. (Nasdaq: DRIO) will announce its financial results for Q1 2022 on May 12, 2022, hosting a conference call and webcast at 8:30 am ET. Key executives, including CEO Erez Raphael, will lead the discussion. Interested participants can join via dial-in or the provided webcast link. A replay will be available after the call until June 12, 2022. DarioHealth specializes in digital therapeutics for chronic conditions, offering an innovative platform that integrates multiple health solutions.
DarioHealth Corp. (Nasdaq: DRIO) showcased a study at the ATTD Conference revealing effective diabetes and weight management outcomes via its integrated digital therapeutics platform. Analyzing data from 715 individuals, nearly two-thirds reduced their BMI by an average of 2.8 units and achieved a 7.4% weight loss. A subgroup with high-risk blood glucose levels experienced a 4.9% weight loss and a 16.1% reduction in blood glucose over 12 months. This study underscores Dario’s holistic approach, which could significantly impact chronic condition management.
DarioHealth Corp. (Nasdaq: DRIO) has announced a partnership with Colorado Access, the largest public sector health plan in Colorado, to enhance digital chronic condition management for underserved populations. Starting in Q2 2022, Dario will provide integrated solutions for members managing diabetes, hypertension, weight, and behavioral health needs. This collaboration aims to deliver personalized care using Dario's comprehensive digital therapeutics platform, combining tools, devices, and coaching. The partnership reflects a growing recognition of the importance of digital health in improving member outcomes.
Summary not available.
DarioHealth Corp. (Nasdaq: DRIO) reported a substantial revenue increase of 171%, reaching $20.5 million for 2021, driven by its B2B growth and acquisitions. The fourth quarter saw a revenue rise to $6.03 million, a 190% year-on-year increase. However, gross profit as a percentage declined to 9.1%. Operating expenses surged to $22.2 million, leading to an operating loss of $21.7 million. A notable collaboration with Sanofi aims to enhance market presence. Cash reserves stood at $35.8 million, supplemented by a $40 million raise in March 2022 to support ongoing strategic initiatives.
DarioHealth Corp. (Nasdaq: DRIO) will release its financial results for the fourth quarter and full year ended December 31, 2021, on March 21, 2022, post-market close. A conference call will be held on March 22, 2022, at 8:30 am EDT, featuring CEO Erez Raphael and other executives. Participants should join 10 minutes early, with a replay available until April 22, 2022. DarioHealth focuses on digital therapeutics to manage chronic conditions through AI-powered tools and personalized experiences.
Summary not available.
DarioHealth Corp. (Nasdaq: DRIO) will participate in the Cowen 42nd Annual Healthcare Conference virtually from March 7-9, 2022. CEO Erez Raphael and President Rick Anderson will hold a fireside chat on March 8 from 11:10-11:40 AM ET. A live webcast will be available here and on their Investor Relations website, with a replay accessible for 90 days. DarioHealth specializes in digital therapeutics, providing solutions for chronic conditions and promoting health improvements through AI-driven, personalized platforms.
DarioHealth Corp. (Nasdaq: DRIO) has announced a strategic agreement with Sanofi U.S., valued at $30 million. This multi-year contract aims to enhance the commercial adoption of Dario's digital therapeutics and expand digital health solutions on its platform. The collaboration will significantly increase Dario's market reach in health plans and employers. Dario will leverage its comprehensive digital therapeutics to help manage chronic conditions, aligning with Sanofi’s goal to integrate healthcare and technology for chronic disease management.
DarioHealth Corp. (Nasdaq: DRIO) announced a registered direct offering on February 28, 2022, with institutional investors, raising approximately $40 million. The sale includes about 5.34 million shares priced at $7.49 each, along with pre-funded warrants. The proceeds will support the expansion of its digital health platform in the U.S. market and further development of new solutions. The offering is expected to close by March 3, 2022. It is conducted under a shelf registration statement with the SEC, ensuring compliance with securities laws.